Agranulocytosis
Welcome,         Profile    Billing    Logout  
 33 Companies   47 Products   47 Products   35 Mechanisms of Action   1 Trial   245 News 


12345»
  • ||||||||||  ANF-Rho (pegfilgrastim biosimilar) / Prolong Pharma
    Trial withdrawal:  ANF-Rho in the Treatment of Chronic Neutropenia (clinicaltrials.gov) -  Mar 6, 2019   
    P1/2,  N=0, Withdrawn, 
    Not yet recruiting --> Withdrawn
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Neutropenic Fever, Inflammatory Markers and Sepsis in Haematological Patients (clinicaltrials.gov) -  Mar 1, 2019   
    P=N/A,  N=273, Completed, 
    Not yet recruiting --> Withdrawn Recruiting --> Completed | Trial completion date: Dec 2016 --> Jan 2019 | Trial primary completion date: Dec 2016 --> Jan 2019
  • ||||||||||  YPEG-filgrastim (YPEG-rhG-CSF) / Xiamen Amoytop Biotech
    Trial completion:  Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) -  Jul 17, 2018   
    P2,  N=80, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> Oct 2018 | Trial primary completion date: Oct 2019 --> Oct 2018 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial primary completion date:  CANHPARI: Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis (clinicaltrials.gov) -  May 1, 2018   
    P=N/A,  N=100, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Jun 2017
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia (clinicaltrials.gov) -  Apr 18, 2018   
    P=N/A,  N=70, Completed, 
    Recruiting --> Completed | Trial primary completion date: Feb 2018 --> Jun 2017 Active, not recruiting --> Completed | Trial completion date: May 2020 --> Apr 2018 | Trial primary completion date: May 2019 --> Apr 2018
  • ||||||||||  Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Diagnostic assay:  Determining the Etiology of Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay (clinicaltrials.gov) -  Mar 6, 2018   
    P=N/A,  N=57, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: May 2020 --> Apr 2018 | Trial primary completion date: May 2019 --> Apr 2018 Recruiting --> Active, not recruiting | N=100 --> 57 | Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Jul 2017 --> Jul 2018
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen, Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
    Trial completion:  A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy. (clinicaltrials.gov) -  Feb 23, 2018   
    P2,  N=138, Completed, 
    Recruiting --> Active, not recruiting | N=100 --> 57 | Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Jul 2017 --> Jul 2018 Recruiting --> Completed
  • ||||||||||  Trial primary completion date:  CANHPARI: Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis (clinicaltrials.gov) -  Aug 1, 2017   
    P=N/A,  N=100, Recruiting, 
    Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Oct 2016 Trial primary completion date: Oct 2017 --> Feb 2018
  • ||||||||||  Amevive (alefacept) / Astellas
    Trial termination:  Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) -  Jun 7, 2017   
    P=N/A,  N=3, Terminated, 
    Recruiting --> Completed Suspended --> Terminated; drug company is no longer making the drug
  • ||||||||||  YPEG-filgrastim (YPEG-rhG-CSF) / Xiamen Amoytop Biotech
    Enrollment closed, Trial primary completion date:  Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) -  Mar 29, 2017   
    P2,  N=80, Active, not recruiting, 
    Recruiting --> Completed | N=128 --> 161 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Mar 2017
  • ||||||||||  Trial completion, Trial primary completion date, Gram negative:  Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% (clinicaltrials.gov) -  Sep 28, 2016   
    P3,  N=60, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2016
  • ||||||||||  vancomycin / Generic mfg., linezolid oral / Generic mfg.
    Enrollment change, Trial termination, Trial primary completion date:  Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer (clinicaltrials.gov) -  Sep 12, 2016   
    P2,  N=2, Terminated, 
    Trial primary completion date: Jun 2016 --> Oct 2016 N=100 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jun 2016; No longer aligned with the revised clinical development plan and commercial strategy
  • ||||||||||  GW003 (balugrastim biosimilar) / Mabwell (Shanghai) Biosci
    Trial primary completion date:  Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects (clinicaltrials.gov) -  Sep 8, 2016   
    P1,  N=30, Recruiting, 
    N=100 --> 2 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jun 2016; No longer aligned with the revised clinical development plan and commercial strategy Trial primary completion date: Jun 2016 --> Dec 2016